The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 16, 2021

Filed:

May. 21, 2019
Applicant:

Nansha Biologics (Hong Kong) Limited, Central, HK;

Inventors:

Kuo-Ming Yu, Taipei, TW;

Qui-Lim Choo, El Cerrito, CA (US);

Manson Fok, The Peak, HK;

Johnson Yiu-Nam Lau, Houston, TX (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/60 (2017.01); C07K 14/54 (2006.01); A61K 9/00 (2006.01); A61K 38/20 (2006.01); A61K 45/00 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 47/60 (2017.08); A61K 9/0019 (2013.01); A61K 38/2073 (2013.01); A61K 45/00 (2013.01); A61K 45/06 (2013.01); C07K 14/5431 (2013.01); A61K 38/00 (2013.01);
Abstract

Methods are provided for treating an individual with a pharmaceutical preparation that includes a recombinant IL-11 PEGylated at equimolar to low molar excess of PEG to achieve a highly pure monoconjugate preparation, which provides improved half-life in serum while having desirable therapeutic activity and presenting fewer side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.


Find Patent Forward Citations

Loading…